Circulating tumour cells and cell-free DNA in pancreatic ductal adenocarcinoma
File(s)
Accepted version
Author(s)
Gall, TM
Belete, S
Khanderia, E
Frampton, AE
Jiao, LR
Type
Journal Article
Abstract
Pancreatic cancer is detected late in the disease process and has an extremely poor prognosis. A blood-based biomarker that can enable early detection of disease, monitor response to treatment, and potentially allow for personalised treatment, would be of great benefit. This review analyses the literature regarding two potential biomarkers: circulating tumour cells (CTCs) and cell-free DNA (cfDNA) with regards to pancreatic ductal adenocarcinoma (PDAC). The origin of CTCs and the methods of detection are discussed and a decade of research examining CTCs in pancreatic cancer is summarized, including both levels of CTCs and analyzing their molecular characteristics, and how this may affect survival in both advanced and early disease and allow for treatment monitoring. The origin of cfDNA is discussed and the literature over the past 15 years is summarized. This includes analyzing cfDNA for genetic mutations and methylation abnormalities which has the potential to be used for PDAC detection and prognosis. However, the research certainly remains in the experimental stage warranting future large trials in these areas.
Date Issued
2019-01-01
Date Acceptance
2018-03-26
Citation
American Journal of Pathology, 2019, 189 (1), pp.71-81
ISSN
0002-9440
Publisher
Elsevier
Start Page
71
End Page
81
Journal / Book Title
American Journal of Pathology
Volume
189
Issue
1
Copyright Statement
© 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
The Alliance Family Foundation
Grant Number
N/A
Subjects
Science & Technology
Life Sciences & Biomedicine
Pathology
K-RAS MUTATIONS
CANCER-PATIENTS
NUCLEIC-ACIDS
PLASMA DNA
PROGNOSTIC-SIGNIFICANCE
EPITHELIAL-CELLS
KRAS MUTATIONS
BIOMARKER
BLOOD
METHYLATION
Pathology
11 Medical and Health Sciences
Publication Status
Published
Date Publish Online
2018-12-14